Cannabis and Drug Interactions: Peer-Reviewed Research Consensus

160 studies analyzedLast updated March 7, 2026

Overview

The research base for cannabis and drug interactions includes 160 peer-reviewed studies spanning 1976–2026. Of these, 18 provide strong evidence, including 4 meta-analyses and 14 randomized controlled trials. Key findings with strong support include: meta-analysis of pivotal trials found cbd has independent anti-seizure effects, though the benefit is amplified by interaction with clobazam, and a meta-analysis of 4 rcts confirmed cbd significantly reduces seizures both with and without clobazam, though the effect was somewhat larger with clobazam. However, several findings remain debated, and the evidence is not uniform across all areas. Many studies have methodological limitations including small sample sizes, short follow-up periods, and reliance on self-reported data.

What the Research Shows

Findings supported by multiple peer-reviewed studies. Stronger evidence means more consistency across study types.

Meta-analysis of pivotal trials found CBD has independent anti-seizure effects, though the benefit is amplified by interaction with clobazam

Strong Evidence
5 studies|Subgroup analyses were not pre-specified. Small numbers in non-clobazam subgroups. Meta-analysis of subgroups has inherent limitations.

A meta-analysis of 4 RCTs confirmed CBD significantly reduces seizures both with and without clobazam, though the effect was somewhat larger with clobazam

Strong Evidence
5 studies|Post-hoc stratified analysis of existing trials, not prospective; the difference in treatment ratios with/without clobazam could reflect a synergistic effect; cannot fully exclude confounding by cloba

Meta-analysis of 4 RCTs (714 patients) showed CBD reduced seizures in Dravet and Lennox-Gastaut syndrome regardless of whether patients were also taking clobazam

Strong Evidence
5 studies|Patients were not randomized to clobazam status (post-hoc subgroup analysis); limited sample sizes in subgroups; all trials used pharmaceutical-grade CBD (Epidiolex).

Where Scientists Disagree

Areas where research shows conflicting results or ongoing scientific debate.

Double-blind crossover study of 24 volunteers found CBD partially inhibits THC liver metabolism, though the effect was small relative to natural variation, and women achieved significantly higher THC blood levels than men

Moderate Evidence
27 studies|Large individual variation in pharmacokinetic data made it difficult to detect definitive effects. The doses used (10 mg THC, 5.4 mg CBD) may not represent all clinical scenarios. The study concluded

Year-long study found combined MDMA and cannabis users had sustained immune cell decreases and more infections, with cannabis-only users showing intermediate effects

Moderate Evidence
27 studies|Polydrug users often use additional substances not accounted for in this study. Self-reported drug use may be inaccurate. The observational design cannot confirm that drug use caused the immune change

Year-long study found ecstasy polydrug users showed mild cognitive decline while cannabis was paradoxically linked to faster brain processing speed on EEG measures

Moderate Evidence
27 studies|Very small sample sizes limit statistical power and generalizability. Ecstasy users were polydrug users, making attribution difficult. Self-reported drug use may be inaccurate. The paradoxical cannabi

A review described how chronic nicotine and alcohol each alter cannabinoid receptors, endocannabinoid content, and multiple other brain systems, reducing each other's withdrawal and increasing preference for combined use

Moderate Evidence
27 studies|Narrative review without systematic methodology. Many findings were from animal studies that may not translate to human experience. The complexity of multi-system interactions makes specific conclusio

What We Still Don't Know

  • Long-term prospective studies tracking outcomes over 5+ years are largely absent from the literature.
  • Research on diverse populations (different ages, ethnicities, and medical backgrounds) remains limited.

Evidence Breakdown

Distribution of study types in this research area. Higher-tier evidence (meta-analyses, RCTs) provides stronger conclusions.

Meta-Analyses & Systematic Reviews(Tier 1)
4 (3%)
Randomized Controlled Trials(Tier 2)
14 (9%)
Observational & Cohort(Tier 3-4)
28 (18%)
Reviews & Scoping(Tier 4)
48 (30%)
Case Reports & Animal(Tier 5)
4 (3%)
Other
62 (39%)

Key Studies

The most impactful research in this area.

CBD reduced seizures in both Dravet and Lennox-Gastaut syndromes, with enhanced effects when combined with clobazam

This meta-analysis directly addresses the critical question of whether CBD's seizure reduction is partly driven by its interaction with clobazam, showing CBD is effective in both clobazam users and the overall population, but more so in the combination.

2021

CBD does have independent anti-seizure effects, though clobazam interaction boosts them

This addresses the critical question of whether CBD is truly anti-epileptic or merely boosting clobazam levels, concluding that both mechanisms contribute.

2020

Meta-analysis of 4 RCTs confirms CBD reduces seizures with and without clobazam co-treatment

A persistent question has been whether CBD's seizure benefit depends on its interaction with clobazam rather than direct anticonvulsant effects. This meta-analysis demonstrates independent efficacy.

2020

CBD works for seizures whether or not patients also take clobazam

A key debate in epilepsy medicine was whether CBD works on its own or only because it boosts clobazam blood levels through a drug interaction. This analysis suggests CBD has independent anti-seizure efficacy.

2020

Phase 1 trial maps CBD drug interactions with three common epilepsy medications

These three AEDs are among the most commonly co-prescribed with CBD for Lennox-Gastaut and Dravet syndromes. Knowing that CBD triples the active clobazam metabolite is clinically actionable: clobazam doses may need reduction when adding CBD.

2019

How Long Cannabis Shows Up in Urine — and Why Current Thresholds May Be Wrong

Urine testing is the most common form of cannabis detection in workplaces, criminal justice, and sport — affecting millions of people. This systematic review demonstrates that current thresholds often detect past use rather than recent consumption or impairment. For regular users trying to quit, wee

2026

Research Timeline

How our understanding of this topic has evolved.

Pre-2000

3 studies published. Includes 2 RCTs.

2000–2009

7 studies published. Includes 1 RCTs.

2010–2014

19 studies published. Predominantly observational and review studies.

2015–2019

43 studies published. Includes 4 RCTs, 5 strong-evidence studies.

2020–present

88 studies published. Includes 4 meta-analyses, 7 RCTs, 13 strong-evidence studies.

About This Consensus

This consensus synthesizes 160 peer-reviewed studies: 4 meta-analyses (3%), 14 randomized controlled trials (9%), 28 observational studies (18%), 48 reviews (30%), 4 case studies (3%), 62 other study types (39%). Studies span from the earliest available research through 2025. Evidence strength ratings reflect study design, sample size, and replication across multiple research groups.

This page synthesizes findings from 160 peer-reviewed studies. It is not medical advice. Always consult a healthcare provider for personal health decisions.